Prevention of thromboembolism in the patient with acute coronary syndrome and atrial fibrillation: The clinical dilemma of triple therapy

Current Opinion in Cardiology

Volumn 29, Issue 1, 2014, Pages 1-9

  Fitchett, David ^a   Verma, Atul ^b   Eikelboom, John ^c   Madan, Mina ^d   Cohen, Eric ^d   Bell, Alan ^d   Dorian, Paul ^a  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b ANIMAL HEALTH TRUST   (United Kingdom)

^c MCMASTER UNIVERSITY   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; APIXABAN; CLOPIDOGREL; DABIGATRAN; IRBESARTAN; PRASUGREL; RIVAROXABAN; TICAGRELOR; WARFARIN;

ACUTE CORONARY SYNDROME; BLEEDING; CLINICAL TRIAL; CORONARY STENT; HEART ATRIUM FIBRILLATION; HUMAN; NON ST SEGMENT ELEVATION ACUTE CORONARY SYNDROME; PRIORITY JOURNAL; REVIEW; STENT THROMBOSIS; THROMBOEMBOLISM;

ACUTE CORONARY SYNDROME; ANTICOAGULANTS; ATRIAL FIBRILLATION; DRUG THERAPY, COMBINATION; HEMORRHAGE; HUMANS; PLATELET AGGREGATION INHIBITORS; PROSTHESIS FAILURE; PURINERGIC P2Y RECEPTOR ANTAGONISTS; STENTS; STROKE; THROMBOEMBOLISM; TREATMENT OUTCOME;

EID: 84890430782     PISSN: 02684705     EISSN: 15317080     Source Type: Journal    
DOI: 10.1097/HCO.0000000000000024     Document Type: Review

References (35)

1. Schmitt J, Duray G, Gersh BJ, Hohnloser SH. Atrial fibrillation in acute myocardial infarction: A systematic review of the incidence, clinical features and prognostic implications. Eur Heart J 2009; 30:1038-1045.
2. Ruiz-Nodar JM, Marin F, Lip GY. Antithrombotic management and type of stent in atrial fibrillation patients undergoing percutaneous coronary intervention. Rev Esp Cardiol 2013; 66:12-16.
3. Bell AD, Roussin A, Cartier R, et al. The use of antiplatelet therapy in the outpatient setting: Canadian cardiovascular society guidelines executive summary. Can J Cardiol 2011; 27:S1-S59.
4. Faxon DP, Eikelboom JW, Berger PB, et al. Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting: A North American perspective-executive summary. Circ Cardiovasc Interv 2011; 4:522-534.
5. Lip GY, Huber K, Andreotti F, et al., Consensus Document of European Society of Cardiology Working Group on Thrombosis. Antithrombotic management of atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing coronary stenting: Executive summary-a consensus document of the European Society of Cardiology Working Group on Thrombosis, endorsed by the European Heart Rhythm Association (EHRA) and the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 2010; 31:1311-1318.
6. Tanguay JF, Bell AD, Ackman ML, et al. Focused 2012 update of the Canadian Cardiovascular Society guidelines for the use of antiplatelet therapy. Can J Cardiol 2013; 29:1334-1345. The canadian consensus document on antiplatelet therapy includes recommendations on therapy for both ACS patients and patients undergoing coronary stenting.
7. Kinjo K, Sato H, Sato H, et al., Osaka Acute Coronary Insufficiency Study Group. Prognostic significance of atrial fibrillation/atrial flutter in patients with acute myocardial infarction treated with percutaneous coronary intervention. Am J Cardiol 2003; 92:1150-1154.
8. Lehto M, Snapinn S, Dickstein K, et al., OPTIMAAL investigators. Prognostic risk of atrial fibrillation in acute myocardial infarction complicated by left ventricular dysfunction: The OPTIMAAL experience. Eur Heart J 2005; 26:350-356.
9. Crenshaw BS, Ward SR, Granger CB, et al. Atrial fibrillation in the setting of acute myocardial infarction: The GUSTO-I experience. Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries. J Am Coll Cardiol 1997; 30:406-413.
10. Bishara R, Telman G, Bahouth F, et al. Transient atrial fibrillation and risk of stroke after acute myocardial infarction. Thromb Haemost 2011; 106:877-884.
11. Siu CW, Jim MH, Ho HH, et al. Transient atrial fibrillation complicating acute inferior myocardial infarction: Implications for future risk of ischemic stroke. Chest 2007; 132:44-49.
12. Leon MB, Baim DS, Popma JJ, et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med 1998; 339:1665-1671.
13. Karjalainen PP, Porela P, Ylitalo A, et al. Safety and efficacy of combined antiplatelet-warfarin therapy after coronary stenting. Eur Heart J 2007; 28:726-732.
14. Mega JL, Braunwald E, Wiviott SD, et al., Investigators AAT. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012; 366:9- The ATLAS ACS 2 TIMI 51 trial in patients with ACS, most of whom were taking dual APT, showed rivaroxaban at a dose 25% of the atrial fibrillation prophylaxis dose improved survival but increased major bleeding.
15. Alexander JH, Lopes RD, James S, et al., Investigators A. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med 2011; 365:699-708.
16. ACTIVE Writing Group of the ACTIVE Investigators. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events (ACTIVE W): A randomised controlled trial. Lancet 2006; 367:1903-1912.
17. ACTIVE Investigators. Connolly SJ, Pogue J, et al. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med 2009; 360:2066-2078.
18. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361:1139-1151.
19. Patel MR, Mahaffey KW, Garg J, et al., Rocket AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365:883-891.
20. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365:981-992.
21. Oldgren J, Budaj A, Granger CB, et al., RE-DEEM Investigators. Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: A randomized, double-blind, phase II trial. Eur Heart J 2011; 32:2781-2789.
22. Mega JL, Braunwald E, Mohanavelu S, et al., ATLAS ACS-TIMI 46 study group. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): A randomised, double-blind, phase II trial. Lancet 2009; 374:29-38.
23. APPRAISE Steering Committee and Investigators. Alexander JH, Becker RC, Bhatt DL, et al. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: Results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. Circulation 2009; 119:2877-2885.
24. Lamberts M, Gislason GH, Olesen JB, et al. Oral anticoagulation and antiplatelets in atrial fibrillation patients after myocardial infarction and coronary intervention. J Am Coll Cardiol 2013; 62:981-989. A large observational study from Denmark in 1200 atrial fibrillation patients with AMI, indicating that OAC with clopidogrel was equal to or better than triple therapy for both benefits and safety.
25. Fitchett DH. Potential role of rivaroxaban in patients with acute coronary syndrome. Drug Des Devel Ther 2012; 6:349-357.
26. Sarafoff N, Martischnig A, Wealer J, et al. Triple therapy with aspirin, prasugrel and vitamin K antagonists in patients with drug eluting stent implantation and an indication for oral anticoagulation. J Am Coll Cardiol 2013; 61:2060-2066. doi:10.1016/S0735-1097(13)61859-8.
27. Dans AL, Connolly SJ, Wallentin L, et al. Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial. Circulation 2013; 127:634-640. This analysis is from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial. It is the only available analysis of the impact on bleeding of adding APT to treatment with a NOAC.
28. Alexander JH, Lopes RD, Thomas L, et al. Apixaban vs warfarin with concomitant aspirin in patients with atrial fibrillation: Insights from the ARISTOTLE trial. Eur Heart J 2013. doi:10.1093/eurheartj/eht445. [Epub ahead of print]
29. Siegal D, Yudin J, Kaatz S, et al. Periprocedural heparin bridging in patients receiving vitamin K antagonists: Systematic review and meta-analysis of bleeding and thromboembolic rates. Circulation 2012; 126:1630-1639.
30. Raunso J, Selmer C, Olesen JB, et al. Increased short-term risk of thromboembolism or death after interruption of warfarin treatment in patients with atrial fibrillation. Eur Heart J 2012; 33:1886-1892.
31. Lip GY, Huber K, Andreotti F, et al., European Society of Cardiology Working Group on Thrombosis. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary intervention/stenting. Thromb Haemost 2010; 103:13-28.
32. Karjalainen PP, Vikman S, Niemela M, et al. Safety of percutaneous coronary intervention during uninterrupted oral anticoagulant treatment. Eur Heart J 2008; 29:1001-1010.
33. Dewilde WJ, Oirbans T, Verheugt FW, et al.,WOEST study investigators. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: An open-label, randomised, controlled trial. Lancet 2013; 381:1107-1115. The WOEST trial is an open label trial in patients undergoing coronary stenting who required anticoagulation with warfarin. Clopidogrel with OAC showed improved outcomes (including less bleeding) than with triple therapy including OAC, aspirin and clopidogrel.
34. Ong AT, Hoye A, Aoki J, et al. Thirty-day incidence and six-month clinical outcome of thrombotic stent occlusion after bare-metal, sirolimus, or paclitaxel stent implantation. J Am Coll Cardiol 2005; 45:947-953.
35. Ong AT, McFadden EP, Regar E, et al. Late angiographic stent thrombosis (last) events with drug-eluting stents. J Am Coll Cardiol 2005; 45:2088-2092.